(lp0
S'Analyst Activity  Piper Jaffray Companies Reiterates Overweight on Corcept ... Market Exclusive - Mar 16, 2017 Today, Piper Jaffray Companies reiterated its Overweight rating on Corcept Therapeutics Incorporated  with a price target of $18.00.Corcept Therapeutics Incorporated  Plunges 7.8% on March 14 - Equities.comAnalyst Recommendations And Earnings Forecast: California Resources ... - Post Analyst'
p1
aS'9.88 MarketWatch - Dec 21, 2009 Corcept Therapeutics Inc. Watchlist CreateCORTAlert. After Hours. Last Updated: Mar 16, 2017 4:49 p.m.. $ 9.88. 0.00 0.00%.'
p2
aS"Corcept Therapeutics Rose 18% in March. Here's Why. Motley Fool - Apr 6, 2016 What: Shares of Corcept Therapeutics , small-cap biopharma focused on developing products for the metabolic, psychiatric, and oncologic markets, gained more than 18% in March, according to data from S&amp;P Global Market Intelligence."
p3
aS"Corcept Therapeutics: Cushing's Syndrome Is Just The Beginning Seeking Alpha - Oct 11, 2016 Shares are up over 40% since the beginning of the year, but there's plenty of upside left based on growth in the company's core business."
p4
aS"Corcept Therapeutics Incorporated's  stock price is Worth at $9.88 while ... Hot Stocks Point - 23 hours ago Corcept Therapeutics Incorporated  stock price ended its day with loss -3.23% and finalized at the value of $9.88. During its last trading session, Stock traded with the total exchanged volume of 1.17 million shares."
p5
aS'Corcept: A Profitable Biotech With A Bright Future Seeking Alpha - Jan 27, 2017 Corcept Therapeutics  is my favorite type of biotech company. It has an approved, marketed product with ramping sales, promising pipeline candidates, and is beginning to turn a profit.'
p6
aS'Insider Trading Activity Corcept Therapeutics Incorporated (NASDAQ:CORT ... Market Exclusive - Feb 28, 2017 On 12/5/2012 G Leonard Baker Jr, Director Buy, 87,131 $1.46 with an average share price of $127,211.26 View SEC Filing 11/23/2012 per share and the total transaction amounting to Daniel Bradbury.Corcept Therapeutics Incorporated  Director Sells $22025000.00 in Stock - The Cerbat GemA Look Ahead For 2 Stocks: Global Blood Therapeutics, Inc. , Corcept ... - Post Analyst'
p7
aS'Corcept Therapeutics Incorporated : Is The Stock Undervalued? Business Review - Mar 17, 2017 The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.'
p8
aS'Corcept Therapeutics Incorporated  Moves Higher on Volume Spike for ... Equities.com - Feb 23, 2017 Corcept Therapeutics Incorporated  traded on unusually high volume on Feb. 23, as the stock gained 1.65% to close at $8.65.Stocks Roundup: EP Energy Corporation , Corcept Therapeutics ... - FactsReporter'
p9
aS'Corcept Therapeutics Appoints Renee D. Gala to Board of Directors Marketwired  - Jun 28, 2016 MENLO PARK, CA-- - Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and&nbsp;...'
p10
a.